HCPCS Code J9355: Injection, Trastuzumab, Excludes Biosimilar, Per 10 mg

Patients with HER2-positive cancers (breast or gastric) who meet clinical criteria and require Herceptin® rather than a biosimilar.

Yes. Dosing is often calculated by body weight and adjusted per treatment protocol.

Most payers, including Medicare, provide coverage for approved indications when documentation supports medical necessity.